Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years

Désirée van der Heijde, David Salonen, Barbara N Weissman, Robert Landewé, Walter P Maksymowych, Hartmut Kupper, Shaila Ballal, Eric Gibson, Robert Wong, Canadian (M03-606) study group, ATLAS study group, Désirée van der Heijde, David Salonen, Barbara N Weissman, Robert Landewé, Walter P Maksymowych, Hartmut Kupper, Shaila Ballal, Eric Gibson, Robert Wong, Canadian (M03-606) study group, ATLAS study group

Abstract

Introduction: Ankylosing spondylitis (AS) is a chronic rheumatic disease associated with spinal inflammation that subsequently leads to progression of structural damage and loss of function. The fully human anti-tumor necrosis factor (anti-TNF) antibody adalimumab reduces the signs and symptoms and improves overall quality of life in patients with active AS; these benefits have been maintained through 2 years of treatment. Our objective was to compare the progression of structural damage in the spine in patients with AS treated with adalimumab for up to 2 years versus patients who had not received TNF antagonist therapy.

Methods: Radiographs from patients with AS who received adalimumab 40 mg every other week subcutaneously were pooled from the Adalimumab Trial Evaluating Long-Term Efficacy and Safety for Ankylosing Spondylitis (ATLAS) study and a Canadian AS study (M03-606). Radiographic progression from baseline to 2 years in the spine of adalimumab-treated patients from these two studies (adalimumab cohort, n = 307) was compared with an historic anti-TNF-naïve cohort (Outcome in AS International Study [OASIS], n = 169) using the modified Stoke AS Spine Score (mSASSS) method.

Results: mSASSS results were not significantly different between the adalimumab cohort and the OASIS cohort, based on baseline and 2-year radiographs. Mean changes in mSASSS from baseline to 2 years were 0.9 for the OASIS cohort and 0.8 for the adalimumab cohort (P = 0.771), indicating similar radiographic progression in both groups. When results for patients in the OASIS cohort who met the baseline disease activity criteria for the ATLAS and Canadian studies (OASIS-Eligible cohort) were analyzed, there was no significant difference in mean change in mSASSS from baseline to 2 years between OASIS-Eligible patients and adalimumab-treated patients; the mean changes in mSASSS were 0.9 for the OASIS-Eligible cohort and 0.8 for the adalimumab cohort (P = 0.744).

Conclusions: Two years of treatment with adalimumab did not slow radiographic progression in patients with AS, as assessed by the mSASSS scoring system, when compared with radiographic data from patients naïve to TNF antagonist therapy.

Trial registration: ClinicalTrials.gov NCT00085644 NCT00195819.

Figures

Figure 1
Figure 1
Probability plot of 2-year progression in the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS). The cumulative probability plot illustrates the change in mSASSS values from baseline to 2 years in the adalimumab cohort (n = 307) and OASIS (n = 169) cohort (patients without total spinal ankylosis). In both cohorts, over 40% of the patients showed some change and about 10% of the patients showed a change of at least 5 in mSASSS from baseline to year 2. No significant differences between the adalimumab and OASIS cohorts were observed. OASIS, Outcome in Ankylosing Spondylitis International Study.

References

    1. Braun J, Bollow M, Remlinger G, Eggens U, Rudwaleit M, Distler A, Sieper J. Prevalence of spondyloarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum. 1998;41:58–67. doi: 10.1002/1529-0131(199801)41:1<58::AID-ART8>;2-G.
    1. Braun J, Bollow M, Neure L, Seipelt E, Seyrekbasan F, Herbst H, Eggens U, Distler A, Sieper J. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum. 1995;38:499–505. doi: 10.1002/art.1780380407.
    1. Heijde D van der, Landewé , Einstein S, Ory P, Vosse D, Ni L, Lin S-L, Tsuji W, Davis JC., Jr Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum. 2008;58:1324–1331. doi: 10.1002/art.23471.
    1. Heijde D van der, Landewé R, Baraliakos X, Houben H, van Tubergen A, Williamson P, Xu W, Baker D, Goldstein N, Braun J, Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum. 2008;58:3063–3070. doi: 10.1002/art.23901.
    1. Heijde D van der, Kivitz A, Schiff MH, Sieper J, Dijkmans BAC, Braun J, Dougados M, Reveille JD, Wong RL, Kupper H, Davis JC, Jr, ATLAS Study Group Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2006;54:2136–2146. doi: 10.1002/art.21913.
    1. Maksymowych WP, Rahman P, Keystone E, Wong R, Inman R, for the M03-606 Study Group Efficacy of adalimumab in active ankylosing spondylitis (AS)-Results of the Canadian AS study [abstract] Arthritis Rheum. 2005;52:S217.
    1. Heijde D van der, Schiff MH, Sieper J, Kivitz A, Wong RL, Kupper H, Dijkmans BAC, Mease PJ, Davis JC, Jr, ATLAS Study Group Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial. Ann Rheum Dis. 2009;68:922–929. doi: 10.1136/ard.2007.087270.
    1. Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, Fischkoff SA, Chartash EK. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum. 2004;50:1400–1411. doi: 10.1002/art.20217.
    1. Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, Salonen D, Rubenstein J, Sharp JT, Tsuji W. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. 2004;50:2264–2272. doi: 10.1002/art.20335.
    1. Heijde D van der, Klareskog L, Rodriguez-Valverde V, Condreanu C, Bolosiu H, Melo-Gomes J, Tornero-Molina J, Wajdula J, Pedersen R, Fatenejad S, TEMPO Study Investigators Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum. 2006;54:1063–1074. doi: 10.1002/art.21655.
    1. Kavanaugh A, Antoni CE, Gladman D, Wassenberg S, Zhou B, Beutler A, Keenan G, Burmester G, Furst DE, Weisman MH, Kalden JR, Smolen J, Heijde D van der. The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year. Ann Rheum Dis. 2006;65:1038–1043. doi: 10.1136/ard.2005.045658.
    1. Ritchlin CT, Haas-Smith SA, Li P, Hicks DG, Schwarz EM. Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest. 2003;111:821–831.
    1. Redlich K, Hayer S, Ricci R, David JP, Tohidast-Akrad M, Kollias G, Steiner G, Smolen JS, Wagner EF, Schett G. Osteoclasts are essential for TNF-alpha-mediated joint destruction. J Clin Invest. 2002;110:1419–1427.
    1. Lam J, Takeshita S, Barker JE, Kanagawa O, Ross FP, Teitelbaum SL. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest. 2000;106:1481–1488. doi: 10.1172/JCI11176.
    1. Heijde D van der, Landewé R. Selection of a method for scoring radiographs for ankylosing spondylitis clinical trials, by the Assessment in Ankylosing Spondylitis Working Group and OMERACT. J Rheumatol. 2005;32:2048–2049.
    1. Heijde D van der, Landewé R, Linden S van der. How should treatment effect on spinal radiographic progression in patients with ankylosing spondylitis be measured? Arthritis Rheum. 2005;52:1979–1985. doi: 10.1002/art.21133.
    1. Wanders AJ, Landewé RB, Spoorenberg A, Dougados M, Linden S van der, Mielants H, Tempel H van der, Heijde DM van der. What is the most appropriate radiologic scoring method for ankylosing spondylitis? A comparison of the available methods based on the Outcome Measures in Rheumatology Clinical Trials filter. Arthritis Rheum. 2004;50:2622–2632. doi: 10.1002/art.20446.
    1. Creemers MC, Franssen MJ, van't Hof MA, Gribnau FW, Putte LB van de, van Riel PL. Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system. Ann Rheum Dis. 2005;64:127–129. doi: 10.1136/ard.2004.020503.
    1. Wanders A, Landewé R, Dougados M, Mielants H, Linden S van der, Heijde D van der. Association between radiographic damage of the spine and spinal mobility for individual patients with ankylosing spondylitis: can assessment of spinal mobility be a proxy for radiologic evaluation? Ann Rheum Dis. 2005;64:988–994. doi: 10.1136/ard.2004.029728.
    1. Powell A, Keeling SO, Lambert RG, Russell AS, Maksymowych WP. Scoring of radiographic progression over 2 years with the mSASSS in ankylosing spondylitis: does training improve reliability? Arthritis Rheum. 2007;56:S256. doi: 10.1002/art.22818.
    1. Wanders A, Heijde D van der, Landewé R, Béhier JM, Calin A, Olivieri I, Zeidler H, Dougados M. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum. 2005;52:1756–1765. doi: 10.1002/art.21054.
    1. Baraliakos X, Listing J, Brandt J, Haibel H, Rudwaleit M, Sieper J, Braun J. Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF-alpha antibody infliximab. Rheumatology (Oxford) 2007;46:1450–1453. doi: 10.1093/rheumatology/kem166.
    1. Sieper J, Appel H, Braun J, Rudwaleit M. Critical appraisal of assessment of structural damage in ankylosing spondylitis. Arthritis Rheum. 2008;58:649–656. doi: 10.1002/art.23260.
    1. Linden S van der, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27:361–368. doi: 10.1002/art.1780270401.
    1. Maksymowych WP, Rahman P, Shojania K, Olszynski WP, Thomson GTD, Ballal S, Wong RL, Inman RD, M03-606 Study Group Beneficial effects of adalimumab on biomarkers reflecting structural damage in patients with ankylosing spondylitis. J Rheumatol. 2008;35:2030–2037.
    1. Maksymowych WP, Landewé R, Conner-Spady B, Dougados M, Mielants H, Tempel H van der, Poole AR, Wang N, Heijde D van der. Serum matrix metalloproteinase 3 is an independent predictor of structural damage progression in patients with ankylosing spondylitis. Arthritis Rheum. 2007;56:1846–1853. doi: 10.1002/art.22589.
    1. Bárdos T, Szabó Z, Czipri M, Vermes C, Tunyogi-Csapó M, Urban RM, Mikecz K, Glant TT. A longitudinal study on an autoimmune murine model of ankylosing spondylitis. Ann Rheum Dis. 2005;64:981–987. doi: 10.1136/ard.2004.029710.
    1. Lories RJ, Daans M, Derese I, Matthys P, Kasran A, Tylzanowski P, Ceuppens JL, Luyten FP. Noggin haploinsufficiency differentially affects tissue responses in destructive and remodeling arthritis. Arthritis Rheum. 2006;54:1736–1746. doi: 10.1002/art.21897.
    1. Lories RJ, Derese I, de Bari C, Luyten FP. Evidence for uncoupling of inflammation and joint remodeling in a mouse model of spondylarthritis. Arthritis Rheum. 2007;56:489–497. doi: 10.1002/art.22372.
    1. Baraliakos X, Listing J, Rudwaleit M, Seiper J, Braun J. The relationship between inflammation and new bone formation in patients with ankylosing spondylitis. Arthritis Res Ther. 2008;10:R104. doi: 10.1186/ar2496.
    1. Maksymowych WP, Chiowchanwisawakit P, Clare T, Pedersen SJ, Østergaard M, Lambert RGW. Inflammatory lesions of the spine on MRI predict the development of new syndesmophytes in ankylosing spondylitis: evidence for coupling between inflammation and ankylosis. Arthritis Rheum. 2009;60:93–102. doi: 10.1002/art.24132.
    1. Maksymowych WP. What do biomarkers tell us about the pathogenesis of ankylosing spondylitis? Arthritis Res Ther. 2009;11:101–102. doi: 10.1186/ar2565.
    1. Baraliakos X, Listing J, Rudwaleit M, Sieper J, Braun J. Evidence for a link between inflammation and new bone formation in ankylosing spondylitis -- a detailed analysis. Ann Rheum Dis. 2008;67(Suppl II):130.
    1. Heidje D van der, Landewé R, Baraliakos X, Hermann K, Houben H, Hsu B, Baker D, Braun J. MRI-inflammation of the vertebral unit (VU) only marginally contributes to new syndesmophyte formation in that unit: a multi-level analysis. Ann Rheum Dis. 2008;67(Suppl II):130.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться